Executive Summary This report aims to analyze the current and future potential of cancer antibodies by examining key fundamentals across the entire pipeline of antibody drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive landscape within the pharmaceutical industry; compound type, therapy area and target type. This report is written for you to identify your competition and understand which targeting strategies are at work within antibody drug development. It allows you to pin-point which competitors drugs’ clinical out-come may have bearing on your own drug development and who are developing sequels to blockbuster drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversely it may reveal unexpected competition for you. Drug targets are the critical link between drugs and their role in the treatment of medical disorders. BioSeeker has surveyed the cancer antibody field and identified 145 drug targets belonging to 253 antibodies. This report, Cancer Antibodies: Competitive Positioning for Success, is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of cancer antibody drugs. In the report, BioSeeker reports on 147 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 253 cancer antibody drugs designed for the treatment of 42 different cancer indications. The highest degree of distinctiveness among cancer antibodies is achieved by sorting each of them according to targeted cancer indication and drug target mix. At the same time we are also identifying peer groups of drugs, that is, drugs we consider suitable for head-to-head comparison during drug development. To fuel the scientific and competitive thinking, BioSeeker opens the gate into the presence and relevance of protein-protein interactions between identified targets of cancer antibodies. No less than 165 protein-protein interactions were recognized among and between 98 of the 145 included antibody drug targets. Why You Should Own Your Own Copy of this Report: - 260+ pages, with almost a hundred different tables and figures. Includes more than 1,000 active links to drug target related resources on the Internet
- A 253 cancer antibody drugs analysis, under development by 102 investigators, covering 480 developmental projects in cancer
- 145 unique, in-depth, drug target validating profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other antibody drug targets, pursued cancer indications, drugs under development, presence in the Cancer Genome Project etc.
- A unique drug target combination breakdown of cancer antibodies into tumor type and developmental stage
- Unique drug-protein target interactome- and protein-protein of drug targets interactome analysis
- Pathway profiling of cancer antibody drug targets
- Pin-point which competitor drugs’ clinical out-come may have bearing on your own drug development
- Who are working on sequels to blockbuster drugs?
- Locate white-spots in the competitive landscape, giving you little or no competition
In all, this report is a serious reference for any professional interested in the development of oncology drug targets and the selection/validation of targeting strategies. Pages: 261 Table of Contents Download TOC in PDF
|
.gif)
.gif)